CUROCELL INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 31,150 KRW | +2.81% |
|
-1.42% | -12.99% |
| 2023 | GenScript ProBio Signs Viral Vector Manufacturing MOU With Curocell for Next-Generation CAR-T Therapy | CI |
| 2023 | Curocell Inc. has completed an IPO in the amount of KRW 32 billion. | CI |
| 1 day | +2.81% | ||
| 1 week | -1.42% | ||
| Current month | -2.81% | ||
| 1 month | -2.20% | ||
| 3 months | -9.84% | ||
| 6 months | +21.68% | ||
| Current year | -12.99% |
1 week
29 850.00
32 150.00
1 month
29 850.0038 500.00
Current year
24 200.0043 000.00
1 year
18 200.0043 000.00
3 years
18 200.0043 000.00
5 years
18 200.0043 000.00
10 years
18 200.0043 000.00
Curocell Inc is a Korea-based company principally engaged in the manufacture, research and development (R&D) of drugs. The Company is also engaged in the development of novel chimeric antigen receptor (CAR)-T therapy technologies targeting novel cancer antigen, the development of CAR-T therapy technologies improving medicinal effect, the development of CAR-T therapy technologies improving existing side effects and the development of CAR-T therapy technologies automating quality analysis.
| 1st Jan change | Capi. | |
|---|---|---|
| -12.99% | 309M | |
| +46.97% | 56.87B | |
| +38.00% | 39.72B | |
| -6.14% | 39.27B | |
| -6.90% | 28.73B | |
| +13.90% | 26.21B | |
| -16.55% | 19.79B | |
| +32.73% | 12.28B | |
| +28.25% | 12.23B | |
| +0.11% | 12.12B |
- Stock Market
- Equities
- A372320 Stock
